Farrukh Awan, MD
Latest in Blood Cancer Treatment
Dr. Farrukh Awan is an associate professor and hematologist-oncologist at UT Southwestern, who specializes in treating people diagnosed with leukemia and lymphoma.
Explore below for his insights on everything from what blood cancers are, the landscape of current and upcoming treatments, clinical trials, new targeted therapies (including a venetoclax-selinexor Phase 1 trial), emerging T-cell therapies for blood cancers like bispecifics and CAR T, and the importance of patient access to these new treatments.
Dr. Awan is also a member of several professional organizations, including the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH). He is also the recipient of the Young Investigator Award from ASCO and has published on many topics, including ibrutinib and acalabrutinib.
Dr. Awan’s Insights
Dr. Awan shares his work background on leukemia and lymphoma, and the overall picture of progress in blood cancer treatment.
Explore how to approach learning about what clinical trials might be the best options and how to discuss them with your doctor.
Dr. Awan shares about one clinical trial (phase 1) he’s a part of in exploring more treatment options for relapsed/refractory lymphoma patients – venetoclax-selinexor.
Dr. Awan describes bispecific T-cell engagers (bispecifics), an emerging T-cell therapy that’s being investigated for the treatment of blood cancers
Learn more about CAR T-cell therapy, an ever-emerging treatment option for some people diagnosed with relapsed/refractory non-Hodgkin lymphoma.
Dr. Awan says there’s still a major issue with lack of access to new and upcoming treatments and resources for many patients.
Thank you so much, Dr. Awan!
More from Hematologist-Oncologists
Irene Ghobrial, MD
Role: Clinical investigator and professor of hematological oncology
Focus: Multiple myeloma, Waldenström’s Macroglobulinemia, early screening, clinical trials
Provider:Dana-Farber Cancer Institute (Boston)
Jacqueline Barrientos, MD
Role: Hematologist, researcher
Focus: Chronic lymphocytic leukemia (CLL), lymphoma, 17p Deletion (Ibrutinib, Acalabrutinib, Venetoclax), IgHV mutation
Provider: Northwell Health (NYC)